Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1

International Journal of Oncology

Volumn 38, Issue 4, 2011, Pages 1093-1101

  Fuse, Miki ^a   Nohata, Nuiro ^a   Kojima, Satoko ^b   Sakamoto, Shinichi ^a   Chiyomaru, Takeshi ^c   Kawakami, Kazumori ^c   Enokida, Hideki ^c   Nakagawa, Masayuki ^c   Naya, Yukio ^b   Ichikawa, Tomohiko ^a   Seki, Naohiko ^a  

^a CHIBA UNIVERSITY   (Japan)

^b TEIKYO UNIVERSITY   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Fascin homolog 1; miR 145; Prostate cancer; Tumor suppressor

Indexed keywords

FASCIN; FASCIN HOMOLOG 1 PROTEIN; MICRORNA; MICRORNA 145; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE CONTROL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

3' UNTRANSLATED REGIONS; BASE SEQUENCE; CARRIER PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION PROFILING; GENES, REPORTER; HUMANS; MALE; MICROFILAMENT PROTEINS; MICRORNAS; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 79952339573     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.919     Document Type: Article

References (38)

1. Haas GP and Sakr WA: Epidemiology of prostate cancer. CA Cancer J Clin 47: 273-287, 1997. (Pubitemid 27405933)
2. Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, Magnuson A and Adami HO: Natural history of early, localized prostate cancer. JAMA 291: 2713-2719, 2004. (Pubitemid 38725420)
3. Rubin MA and De Marzo AM: Molecular genetics of human prostate cancer. Mod Pathol 17: 380-388, 2004. (Pubitemid 41646614)
4. Chu KC, Tarone RE and Freeman HP: Trends in prostate cancer mortality among black men and white men in the United States. Cancer 97: 1507-1516, 2003. (Pubitemid 36297781)
5. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
6. Bartel DP and Chen CZ: Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet 5: 396-400, 2004. (Pubitemid 38529411)
7. Kloosterman WP and Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell 11: 441-450, 2006. (Pubitemid 44430905)
8. Filipowicz W, Bhattacharyya SN and Sonenberg N: Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 9: 102-114, 2008.
9. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR and Golub TR: MicroRNA expression profiles classify human cancers. Nature 435: 834-838, 2005. (Pubitemid 40839735)
10. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006.
11. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, Yfantis HG, Stephens RM and Croce CM: Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 68: 6162-6170, 2008.
12. Ozen M, Creighton CJ, Ozdemir M and Ittmann M: Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 27: 1788-1793, 2008. (Pubitemid 351380263)
13. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL and Visakorpi T: MicroRNA expression profiling in prostate cancer. Cancer Res 67: 6130-6135, 2007. (Pubitemid 47037493)
14. Prueitt RL, Yi M, Hudson RS, Wallace TA, Howe TM, Yfantis HG, Lee DH, Stephens RM, Liu CG, Calin GA, Croce CM and Ambs S: Expression of microRNAs and protein-coding genes associated with perineural invasion in prostate cancer. Prostate 68: 1152-1164, 2008.
15. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G and Jung K: Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 126: 1166-1176, 2010.
16. Tong AW, Fulgham P, Jay C, Chen P, Khalil I, Liu S, Senzer N, Eklund AC, Han J and Nemunaitis J: MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther 16: 206-216, 2009.
17. Zaman MS, Chen Y, Deng G, Shahryari V, Suh SO, Saini S, Majid S, Liu J, Khatri G, Tanaka Y and Dahiya R: The functional significance of microRNA-145 in prostate cancer. Br J Cancer 103: 256-264, 2010.
18. Chiyomaru T, Enokida H, Tatarano S, Kawahara K, Uchida Y, Nishiyama K, Fujimura L, Kikkawa N, Seki N and Nakagawa M: miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer 102: 883-891, 2010.
19. Arndt GM, Dossey L, Cullen LM, Lai A, Druker R, Eisbacher M, Zhang C, Tran N, Fan H, Retzlaff K, Bittner A and Raponi M: Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer 9: 374, 2009.
20. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, Calin GA, Menard S and Croce CM: MicroRNA signatures in human ovarian cancer. Cancer Res 67: 8699-8707, 2007. (Pubitemid 47437445)
21. Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M and Matsubara H: miR-145, miR-133a and miR-133b: Tumor suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer 127: 2804-2814, 2010.
22. Akao Y, Nakagawa Y, Kitade Y, Kinoshita T and Naoe T: Downregulation of microRNAs-143 and -145 in B-cell malignancies. Cancer Sci 98: 1914-1920, 2007.
23. Sachdeva M and Mo YY: miR-145-mediated suppression of cell growth, invasion and metastasis. Am J Transl Res 2: 170-180, 2010.
24. Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, Kawamoto K, Kawahara K, Told K, Kawakami K, Nishiyama K, Tsujimoto G, Nakagawa M and Seki N: Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer 125: 345-352, 2009.
25. Kikkawa N, Hanazawa T, Fujimura L, Nohata N, Suzuki H, Chazono H, Sakurai D, Horiguchi S, Okamoto Y and Seki N: miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma (HSCC). Br J Cancer 103: 877-884, 2010.
26. Sugimoto T, Seki N, Shimizu S, Kikkawa N, Tsukada J, Shimada H, Sasaki K, Hanazawa T, Okamoto Y and Hata A: The g alanin signaling cascade is a candidate pathway regulating oncogenesis in human squamous cell carcinoma. Genes Chromosomes Cancer 48: 132-142, 2009.
27. Shi B, Sepp-Lorenzino L, Prisco M, Linsley P, deAngelis T and Baserga R: Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J Biol Chem 282: 32582-32590, 2007. (Pubitemid 350159311)
28. Sachdeva M and Mo YY: MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res 70: 378-387, 2010.
29. Hashimoto Y, Skacel M and Adams JC: Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker? Int J Biochem Cell Biol 37: 1787-1804, 2005.
30. Vignjevic D, Kojima S, Aratyn Y, Danciu O, Svitkina T and Borisy GG: Role of fascin in filopodial protrusion. J Cell Biol 174: 863-875, 2006. (Pubitemid 44373735)
31. Pelosi G, Pasini F, Fraggetta F, Pastorino U, Iannucci A, Maisonneuve P, Arrigoni G, De Manzoni G, Bresaola E and Viale G: Independent value of fascin immunoreactivity for predicting lymph node metastases in typical and atypical pulmonary carcinoids. Lung Cancer 42: 203-213, 2003. (Pubitemid 37268031)
32. Darnel AD, Behmoaram E, Vollmer RT, Corcos J, Bijian K, Sircar K, Su J, Jiao J, Alaoui-Jamali MA and Bismar TA: Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer. Clin Cancer Res 15: 1376-1383, 2009.
33. Hashimoto Y, Ito T, Inoue H, Okumura T, Tanaka E, Tsunoda S, Higashiyama M, Watanabe G, Imamura M and Shimada Y: Prognostic significance of fascin overexpression in human esophageal squamous cell carcinoma. Clin Cancer Res 11: 2597-2605, 2005. (Pubitemid 40569459)
34. Grothey A, Hashizume R, Sahin AA and McCrea PD: Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer. Br J Cancer 83: 870-873, 2000.
35. Jawhari AU, Buda A, Jenkins M, Shehzad K, Sarraf C, Noda M, Farthing MJ, Pignatelli M and Adams JC: Fascin, an actin-bundling protein, modulates colonic epithelial cell invasiveness and differentiation in vitro. Am J Pathol 162: 69-80, 2003. (Pubitemid 36041990)
36. Maitra A, Adsay NV, Argani P, Iacobuzio-Donahue C, De Marzo A, Cameron JL, Yeo CJ and Hruban RH: Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol 16: 902-912, 2003. (Pubitemid 37152020)
37. Lin CK, Chao TK, Yu CP, Yu MH and Jin JS: The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters. APMES 117: 162-175, 2009.
38. Goncharuk VN, Ross JS and Carlson JA: Actin-binding protein fascin expression in skin neoplasia. J Cutan Pathol 29: 430-438, 2002.